Overview Safety and Efficacy Study in Adult Subjects With Acute Migraines Status: Completed Trial end date: 2018-01-26 Target enrollment: Participant gender: Summary The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines Phase: Phase 3 Details Lead Sponsor: Biohaven Pharmaceutical Holding Company Ltd.Biohaven Pharmaceuticals, Inc.